Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus INDIUM IN 111 PENTETREOTIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus INDIUM IN 111 PENTETREOTIDE KIT.
AN-DTPA vs INDIUM IN-111 PENTETREOTIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical